Center Advisors, Treatment Development & Evaluation Core

Edward V. Nunes, MD

Professor of Psychiatry, Columbia University Irving Medical Center

General Psychiatry / Psychology; Depression; Anxiety Disorders; Alcoholism; Substance Use; Alcohol Use Disorders; Opioid Use Disorders


Edward V. Nunes, MD
Professor of Psychiatry, Columbia University Irving Medical Center

New York State Psychiatric Institute, 1051 Riverside Drive, Unit 51 New York, NY 10032


Selected Publications
  • Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019 Feb 1;176(2):129-137. doi: 10.1176/appi.ajp.2018.17070732. PMID: 30336703.
  • Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. PMID: 29150198.
  • Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Bonnie RJ, Gordon M, Chen DT, Boney TY, O'Brien CP. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction. 2017 Aug;112(8):1440-1450. doi: 10.1111/add.13807. PMID: 28239984; PMCID: PMC5503784.
  • Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV. Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry. 2017 May 1;174(5):459-467. doi: 10.1176/appi.ajp.2016.16050548. PMID: 28068780.
  • Campbell AN, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, Turrigiano E, Walters S, McClure EA, Kyle TL, Wahle A, Van Veldhuisen P, Goldman B, Babcock D, Stabile PQ, Winhusen T, Ghitza UE. Internet-delivered treatment for substance abuse: A multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683-90. PMID: 24700332.
  • Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction. 2013 Jun;108(6):1084-94. doi: 10.1111/add.12108. PMID: 23297841.
  • Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D. Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction. 2013 Jan;108(1):115-23. doi: 10.1111/j.1360-0443.2012.04010.x. PMID: 22775406.
  • Campbell AN, Nunes EV, Miele GM, Matthews A, Polsky D, Ghitza UE, Turrigiano E, Bailey GL, VanVeldhuisen P, Chapdelaine R, Froias A, Stitzer ML, Carroll KM, Winhusen T, Clingerman S, Perez L, McClure E, Goldman B, Crowell AR. Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: An example from the NIDA Clinical Trials Network. Contemp Clin Trials. 2012;33(2):386-95. PMID: 22085803; PMCID: PMC3268951.
  • Nunes EV, Rounsaville BJ. Comorbidity of substance use with depression and other mental disorders: From Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) to DSM-V. Addiction. 2006 Sep;101 Suppl 1:89-96. doi: 10.1111/j.1360-0443.2006.01585.x. Review. PMID: 16930164.